Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.66 |
| ▸ | PPARG | P37231 | 7/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28651771 | 0.84 | EPHX2 (0.64) | EPHX2PPARGHPGDCYP4F2CYP4A11 | |
| SCHEMBL28926992 | 0.83 | EPHX2 (0.62) | EPHX2PPARGCYP4F2CYP4A11 | |
| SCHEMBL16672593 | 0.82 | CYP4F2 (0.63) | EPHX2PPARGCYP4F2CYP4A11 | |
| SCHEMBL22987233 | 0.81 | EPHX2 (0.69) | EPHX2PPARGROCK2ROCK1PPARA | |
| SCHEMBL28656783 | 0.80 | EPHX2 (0.60) | EPHX2PPARGHPGD | |
| SCHEMBL13947519 | 0.80 | EPHX2 (0.66) | EPHX2PPARGHPGDROCK2ROCK1 | |
| SCHEMBL16672732 | 0.78 | CYP4F2 (0.57) | EPHX2PPARGCYP4F2CYP4A11 | |
| SCHEMBL28663154 | 0.76 | MAPK14 (0.65) | EPHX2PPARGHPGDPPARAHTT | |
| SCHEMBL7398013 | 0.76 | CYP4F2 (0.60) | EPHX2PPARGCYP4F2CYP4A11 | |
| SCHEMBL28646196 | 0.75 | PPARG (0.60) | EPHX2PPARGHPGDROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026028-B | Treatment of diabetes and metabolic syndrome with novel dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors | 威斯康星州医药大学股份有限公司 | 2021-11-09 | — | — | CN | disclosed |